Patents by Inventor Christopher David Floyd

Christopher David Floyd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6258851
    Abstract: Compounds of formula (I), wherein A, B, X, R1, R2, R3, R4, R5, R6 are as defined in the specification, are matrix metalloproteinase inhibitors.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: July 10, 2001
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Christopher David Floyd, Sanjay Ratilal Patel, Mark Whittaker
  • Patent number: 6228988
    Abstract: The present invention describes processes for preparing desired synthetic products that comprise a covalently bonded hydroxamic acid group —CONHOH by forming a mixture of a liquid reaction medium and a solid phase reaction product that carries a plurality of moieties of formula (A1) or (B1): where X is a residual, non-hydroxamate partial structure of the desired synthetic product, P1 is hydrogen or an amino-protecting group, P2 is hydrogen or a hydroxyl protecting group, and the bond designated (a) covalently links the moieties (A1) or (B1) to the residue of a solid substrate; by cleaving the bond designated (a) in the resultant mixture; and by separating the resultant liquid reaction phase from the resultant reaction solids to recover the desired synthetic product.
    Type: Grant
    Filed: June 9, 1999
    Date of Patent: May 8, 2001
    Assignee: British Biotech Pharmaceuticals, Ltd.
    Inventors: Christopher David Floyd, Christopher Norman Lewis
  • Patent number: 6103739
    Abstract: A compound of general formula (I), wherein X is a group of formula (II) or (III), R.sub.2, R.sub.1, R.sub.21, R.sub.3, R.sub.4, and R.sub.5 being as defined in the specification are matrix metalloproteinase inhibitors.
    Type: Grant
    Filed: April 22, 1998
    Date of Patent: August 15, 2000
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Christopher David Floyd, Raymond Paul Beckett, Mark Whittaker, Andrew Miller
  • Patent number: 6093798
    Abstract: The present invention describes solid phase reaction products of a solid substrate carrying a plurality of covalently bound hydroxylamine or protected hydroxylamine groups of formula (A) or (B): ##STR1## where P.sub.1 is hydrogen or an amino protecting group, P.sub.2 is hydrogen or a hydroxyl protecting group, and the bond designated (a) covalently links the formula (A) or (B) to the residue of the solid substrate, and is cleavable under acid conditions or by photolysis. The solid phase reaction products can be used for the synthesis of hydroxamic acid derivatives or a combinatorial library of such compounds.
    Type: Grant
    Filed: June 9, 1999
    Date of Patent: July 25, 2000
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Christopher David Floyd, Christopher Norman Lewis
  • Patent number: 5932695
    Abstract: This invention is direct to a solid phase reaction product of a solid substrate carrying a plurality of covalently bound hydroxylamine or protected hydroxylamine groups. The solid solid phase reaction product may be used for the synthesis of hydroxamic acid derivatives or a combinatorial library of such compounds.
    Type: Grant
    Filed: March 24, 1997
    Date of Patent: August 3, 1999
    Assignee: British Biotech Pharmaceuticals Ltd.
    Inventors: Christopher David Floyd, Christopher Norman Lewis
  • Patent number: 5849951
    Abstract: A method for the preparation of a compound of formula (I) ##STR1## wherein X is hydrogen; Y is (i) a group --CO.sub.2 R.sub.5 wherein R.sub.5 is a carboxyl protecting group or (ii) a group --CONR.sub.6 OR.sub.7 wherein R.sub.6 is an amino protecting group and R.sub.7 is a hydroxyl protecting group; and S.sub.1, S.sub.2, S.sub.3 and S.sub.4 each represent covalently bound moieties which are substantially non-reactive with the reaction components (II), (III), or (IV) defined below, which method comprises causing the co-condensation in a liquid organic medium of a carboxylic acid reaction component of formula (II); an aldehyde of formula (IIIA); ammonia; and an isonitrile reaction component of formula (IV): ##STR2## wherein Y, S.sub.1, S.sub.2, S.sub.3 and S.sub.4 are as defined with respect to formula (I).
    Type: Grant
    Filed: August 29, 1997
    Date of Patent: December 15, 1998
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Christopher David Floyd, Mark Whittaker
  • Patent number: 5741794
    Abstract: Compounds of formula (I), wherein: A represents: a) a --VR.sup.6 group wherein v is --C(.dbd.O), --C(.dbd.O)O--, --CH.sub.2 O--, --CH.sub.2 OC(.dbd.O)--, --C(.dbd.S)--, --CH.sub.2 OC(.dbd.O)NH--, --C(.dbd.S)O--, --CH.sub.2 S--, --C(.dbd.O)NHSO.sub.2 --, --SO.sub.2 NHC(.dbd.O)-- or --CH.sub.2 OSiPh.sub.2 --; b) a --CH.sub.2 NR.sup.9 R.sup.10 group or a --CONR.sup.9 R.sup.10 group wherein each of R.sup.9 and R.sup.10 is independently hydrogen, -alkyl-, -alkenyl-, -alkynyl, -cycloalkyl, -cycloalkenyl, pyridyl (any of which may optionally be substituted) or a group --D as defined above or R.sup.9 and R.sup.10 together with the nitrogen atom to which they are attached form a nitrogen-containing heterocyclic ring; c) a group Y where Y is a 5- or 6-membered optionally substituted heterocyclic ring containing one or more heteroatoms selected from nitrogen, oxygen and sulphur; or d) a group --CH.sub.2 Y or --C(.dbd.
    Type: Grant
    Filed: September 1, 1994
    Date of Patent: April 21, 1998
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Stephen Arthur Bowles, Christopher David Floyd, Andrew Miller, Mark Whittaker, Lars Michael Wood